| 0 (0%) | 09-27 09:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.71  |
1-year : | 14.85 |
| Resists | First : | 10.89 |
Second : | 12.71 |
| Pivot price | 10.66 |
|||
| Supports | First : | 10.34 |
Second : | 10.01 |
| MAs | MA(5) : | 10.83 |
MA(20) : | 10.51 |
| MA(100) : | 10.35 |
MA(250) : | 10.72 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 96.7 |
D(3) : | 97.6 |
| RSI | RSI(14): 73.3 |
|||
| 52-week | High : | 11.76 | Low : | 9.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BHV ] has closed below upper band by 21.3%. Bollinger Bands are 56.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.91 - 10.96 | 10.96 - 11.01 |
| Low: | 10.7 - 10.76 | 10.76 - 10.81 |
| Close: | 10.76 - 10.86 | 10.86 - 10.93 |
Mon, 22 Sep 2025
Megève invites itself to the BHV Marais: a foretaste of alpine winter in Paris - Paris Select Book
Thu, 04 Sep 2025
BHV to bring first production units of SportsBox to IBC 2025 - NewscastStudio
Fri, 30 May 2025
Biohaven initiates Phase II/III trial of BHV-8000 for early Parkinson’s - Clinical Trials Arena
Thu, 22 May 2025
Area Baseball: BHV eliminates PRB in Section 5-1A - Brainerd Dispatch
Thu, 17 Apr 2025
Biohaven’s BHV-8000 rescues locomotor deficits in Parkinson’s disease - BioWorld MedTech
Mon, 07 Apr 2025
Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine (S11.004) - Neurology® Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 2 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 6.9 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | 0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.14 |
| Profit Margin | 20.1 % |
| Operating Margin | 75.1 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 0.89 |
| Sales Per Share | 0.89 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 60.28 |
| PEG Ratio | 0 |
| Price to Book value | 0.89 |
| Price to Sales | 12.14 |
| Price to Cash Flow | 21.98 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|